Corporate Member Update: Merck

Corporate Member Update: Merck

Keytruda
December, 2023

Merck would like to inform you that the FDA has approved KEYTRUDA® (pembrolizumab) Injection 100 mg, in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).

Read the information here!

 
 
Become a NOS Member Today!
Join Now
 

Platinum Corporate Members

Gold Corporate Members